SEEKYO® is a privately owned biotech company focusing on providing cancer patients with improved treatment options limiting adverse effects of standard chemotherapy.

We are developing the next generation of selective drug delivery system designed to treat solid and hematological cancers.

We are targeting cancer cell and tumor microenvironment specificities.